Cenexi integration delays
Integration of Cenexi may face operational challenges, delaying synergy realization and margin improvement.
GLAND / Q1-FY24 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
U.S. pricing pressure from Chinese competitors
Aggressive pricing by Chinese players in injectables could pressure margins, though management sees recent stabilization.
Dependence on enoxaparin recovery
Enoxaparin sales recovery is critical for U.S. growth; any further delays could impact revenue.
Cenexi summer shutdown impact
Annual four-week summer shutdown at Cenexi may temporarily affect revenue and margins in Q2.